In 2025, Trasis continues to drive innovation in nuclear medicine—enabling the development and industrialization of cutting-edge radiotracers and advancing the automated radiolabelling of antibody fragments.

Our mission? To enhance diagnostic accuracy, streamline and secure nuclear medicine workflows, and ensure consistent, reproducible, GMP-compliant results. Today, we’re excited to introduce our latest commercially available innovations, designed to support researchers and pharmaceutical companies in bringing next-generation radiopharmaceuticals to clinical and commercial scale.

Discover our first newsletter in 2025

⁶⁸Ga target purification: a versatile solution for radioisotope production

A ready-to-use process and kit for purifying cyclotron-produced gallium-68! This solution, compatible with both solid and liquid targets, improves and ensures the purity of gallium-68. It meets the increasing quality requirements for radiotracer production while being fully compatible with existing radiolabeling processes.

Contact us

⁸⁹Zr-Biomolecule: a universal process for the automated labelling of antibody fragments

This first industrial automation of antibody labelling enables imaging of various pathologies based on the selected antibody. This major technological breakthrough simplifies the automation of complex labeling processes. The process developed by Trasis is universal and compatible with all biomolecules carrying a DFO or DFO* group.

Contact us

¹⁸F-Octreotide: An Innovative Fluorinated Alternative

[¹⁸F]NOTA-Octreotide is a more accessible fluorinated alternative, enhancing diagnostic precision for neuroendocrine tumors (NETs).

The automated solution implemented by Trasis is universal and compatible with all peptides equipped with a NOTA chelator. Additionally, it integrates seamlessly into standard production equipment, facilitating its adoption into existing manufacturing workflows.

Contact us

Rapid, efficient and simple automated ¹¹C-Acetate labelling

Trasis continues to streamline ¹¹C-tracers syntheses with its ready-to-use ¹¹C-acetate consumables and a dedicated, fully automated sequence on the AllinOne synthesizer.

This radiotracer is essential for imaging cardiac diseases and specific oncological pathologies of the pancreas, kidneys, and prostate

Contact us

Related contents

Trasis will attend JFMN from March 20 to 22

Automated synthesis of 68 Ga/177 Lu-PSMA on the Trasis miniAllinOne